COMMUNIQUÉS West-GlobeNewswire

Entera Bio Presents Positive New Clinical Data from EB613 Phase 2 Trial Demonstrating Significant Bone Density Improvements in Early Postmenopausal Women
23/10/2025
Consistency of BMD gains presented at NAMS 2025 demonstrate EB613’s efficacy in both young postmenopausal women and in women 10 years post-menopause Data further support EB613 potential as a first-in-class oral anabolic [...]
SciSparc Targets Quantum-Powered 3D Protein Modeling Technology to Revolutionize AI Drug Discovery
23/10/2025
TEL AVIV, Israel, Oct. 23, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat [...]
Global Drug Delivery Systems (DDS) Market Transforms Amid New Pharma Demands
23/10/2025
New Alira Health Report Reveals Digital and Sustainable Innovations Driving Drug Delivery Market FRAMINGHAM, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Alira Health today released its 2025 Global Drug Delivery System [...]
GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies
23/10/2025
The formal safety review of Cohort 3 (5ug/kg/day) has been successfully completed with no safety or tolerability issues observed, allowing advancement into Cohort 4 with a dose of 10 ug/kg/day Actively screening [...]
Gelteq Announces Commencement of Preclinical Trial Targeting Oil Soluble Drug Market with Novel Delivery Platform
23/10/2025
Collaboration with Monash University to Address a Large Pharmaceutical Opportunity MELBOURNE, Australia, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based company [...]
Visory Health Partners with Albertsons Companies to Expand Access to Affordable Prescriptions Nationwide
23/10/2025
The health tech company adds more than 1,700 Albertsons Cos. pharmacies to its partnership base of over 37,000 locations ESTERO, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Visory Health , a patient-first health tech [...]
Synfini Selected for SLAS 2026 Innovation AveNEW Showcase
23/10/2025
Company Selected to Demonstrate its Novel AI Foundry That Unites Virtual and Physical Chemistry, Reducing the Time and Cost of Modern Molecular Discovery MENLO PARK, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Synfini , [...]
Solana Company (NASDAQ: HSDT) Strengthens Treasury Strategy with Helius, Anchorage Digital and Twinstake Staking Services
23/10/2025
NEWTOWN, Pa., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Solana Company (NASDAQ: HSDT or the “ Company ”) announced that it has entered into agreements with Helius and Twinstake (each, a “ Provider ,” and collectively, the “ [...]
Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence
23/10/2025
CARLSBAD, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, announced today the acceptance of six abstracts at the 2025 American College of Rheumatology’s ( [...]
BeautyHealth to Report Third Quarter 2025 Financial Results on November 6, 2025
23/10/2025
LONG BEACH, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- The Beauty Health Company (NASDAQ:SKIN), home to flagship brand Hydrafacial™, today announced it will report third quarter 2025 financial results after market close [...]
IMUNON to Present New Translational Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting
23/10/2025
IMNN-001 program is currently advancing its OVATION 3 pivotal Phase 3 trial per plan LAWRENCEVILLE, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN) , a clinical-stage company in Phase 3 development [...]
PCI Biotech update
23/10/2025
Oslo (Norway), 23 October 2025 – PCI Biotech (OSE: PCIB) today provides an update on the ongoing evaluation of its operations. Reference is made to the company’s announcements dated 18 th August 2025 and 25 th September [...]
Abalos Therapeutics Doses First Patient in Phase 1 Study Evaluating ABX-001 for the Treatment of Solid Tumors
23/10/2025
-- First-in-class non-oncolytic arenavirus-based approach designed to induce targeted, effective, and durable anti-cancer activity against primary tumors and metastases – -- Phase 1 study to evaluate the safety and [...]
Hydreight Reports Corporate Update and Ranks #25 on Deloitte’s 2025 Technology Fast 50™
23/10/2025
Over 295,000 VSDHOne product orders between July and September, accelerating nurse network growth and a strong balance sheet with approximately CA$18.7 million in cash; Hydreight continues to build the infrastructure [...]
Silver Creek Pharmaceuticals Announces Positive Phase 2 Results for Scp776 in Acute Ischemic Stroke
23/10/2025
Key Highlights Scp776 is the first therapy to show clinically meaningful efficacy in late-window stroke patients (treated up to 24 hours after onset) – a population with no approved drug options. Scp776 was safe and [...]
'The World’s Greatest Health Van' Travels to Ottawa: 150,000 Canadians Call for The Charter of Health Freedom
23/10/2025
OTTAWA, Ontario, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Shawn Buckley, President of the Natural Health Product Protection Association (NHPPA), is on the road — destination Parliament Hill, Ottawa. His main purpose is to [...]
Pharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific Meeting
23/10/2025
ZUG, Switzerland, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living [...]
TLX250-CDx (Zircaix) Included in Leading International Guidelines for Renal Imaging
23/10/2025
MELBOURNE, Australia and INDIANAPOLIS, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today welcomes updated guidelines from the Society of Nuclear Medicine and [...]
Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers
23/10/2025
– 2L MTAP-del pancreatic cancer median progression free survival (mPFS) 7.2 months with an objective response rate (ORR) of 25% – – Combination studies with RAS(ON) inhibitors ongoing, data anticipated 2026 – – 49% ORR [...]

Pages